<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376011</url>
  </required_header>
  <id_info>
    <org_study_id>1 K23AG030967-01A1-2</org_study_id>
    <secondary_id>1K23AG030967-01A1</secondary_id>
    <nct_id>NCT01376011</nct_id>
  </id_info>
  <brief_title>Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement</brief_title>
  <acronym>Quercetin</acronym>
  <official_title>Hypoxia-inducible Transcription Factor 1 (HIF-1) in Vascular Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if quercetin can increase blood levels of
      hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a
      corresponding increase in blood flow to the brain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define change from baseline levels of HIF-1 concentration and 3 of its regulated proteins after 6 months of quercetin (versus placebo) dietary intake.</measure>
    <time_frame>6 months</time_frame>
    <description>Baseline and 6 month blood samples will be analyzed for levels of HIF-1, VEGF, EPO, and NOS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine change from baseline brain blood flow after 6 months of quercetin (versus placebo) dietary intake.</measure>
    <time_frame>6 months</time_frame>
    <description>Determine cerebral vasomotor reactivity response to 6 months of quercetin intake by measuring changes in middle cerebral artery (MCA) blood flow velocity in response to changes in end-tidal CO2, and assess neurovascular coupling by measuring changes in MCA flow velocity in response to neuropsychological tasks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define change from baseline performance in a battery of cognitive tasks after 6 months of quercetin (versus placebo) dietary intake.</measure>
    <time_frame>6 months</time_frame>
    <description>Assess effects of 6 months of quercetin intake on cognitive function using a cognitive battery designed to asses both memory and executive function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Stroke</condition>
  <condition>Problem of Aging</condition>
  <arm_group>
    <arm_group_label>healthy young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>quercetin/placebo</intervention_name>
    <description>Quercetin 500mg once per day versus placebo</description>
    <arm_group_label>healthy young</arm_group_label>
    <arm_group_label>healthy old</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers between the ages of 18-75 years old

        Exclusion Criteria:

          -  subjects taking vasoactive medications

          -  hypertension or vascular disease

          -  asthma

          -  smokers

          -  pregnant women

          -  cancer

          -  diabetes mellitus

          -  history of seizures

          -  history of stroke or head trauma

          -  subjects taking digoxin, cyclosporine,felodipine, estradiol, or quinolone antibiotics

          -  poor transcranial Doppler insonation windows
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farzaneh Sorond, mD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Farzaneh Sorond</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>quercetin</keyword>
  <keyword>brain blood flow</keyword>
  <keyword>aging</keyword>
  <keyword>memory</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

